Patents Examined by Niloofar Rahmani
  • Patent number: 11407771
    Abstract: Compounds that inhibit mitogen-activated protein kinases (MAPKs) are disclosed. Some inhibitor compounds specifically target a single MAPK such as MAPK13, while others target multiple MAPKs such as MAPK13 and MAPK12. The compounds can be used therapeutically for a variety of diseases, including cancer and respiratory diseases. Methods of synthesis of the compounds are also disclosed.
    Type: Grant
    Filed: May 30, 2019
    Date of Patent: August 9, 2022
    Assignee: Washington University
    Inventors: Michael J. Holtzman, Arthur G. Romero, Benjamin J. Gerovac, Zhenfu Han, Shamus P. Keeler, Kangyun Wu
  • Patent number: 11407767
    Abstract: This invention related to compounds that are inhibitors of the CDK12 kinase. The compounds are useful in the treatment of disorders mediated by the CDK12 kinase including myotonic dystrophy type 1 (DM1) and other disorders caused by the generation of RNA repeat expansion transcripts. In particular, the invention relates to compounds of the formula (I), or a pharmaceutically acceptable salts or N-oxides thereof, wherein R1a, R2, R3, R4a, R4b and R4c are as defined herein.
    Type: Grant
    Filed: September 21, 2018
    Date of Patent: August 9, 2022
    Inventors: David Brook, Chris Hayes, Nicholas Bennett, Matthew Palframan, Sue Cramp, Richard Bull, Michael Bodnarchuk
  • Patent number: 11396514
    Abstract: The present invention provides a compound of general formula (I) (wherein X is as described in the present description and claims), or a pharmacologically acceptable salt thereof, and a pharmaceutical composition containing that compound.
    Type: Grant
    Filed: December 27, 2017
    Date of Patent: July 26, 2022
    Inventors: Ken-ichi Komori, Akishi Ninomiya, Shigeru Ushiyama, Masaru Shinohara, Koji Ito, Tetsuo Kawaguchi, Yasunori Tokunaga, Hiroyoshi Kawada, Haruka Yamada, Yusuke Shiraishi, Masahiro Kojima, Masaaki Ito, Tomio Kimura
  • Patent number: 11384073
    Abstract: The present disclosure relates to a maleate salt of a benzothiophene compound, a crystalline form thereof, and a use thereof. Specifically, the present disclosure relates to a compound represented by formula (I-A), a crystalline form A thereof, a preparation method of a pharmaceutical composition including the same, and a use of the pharmaceutical composition in the preparation of drugs for preventing or treating diseases of the central nervous system. The compound represented by formula (I-A) and the crystalline form A thereof in the present disclosure have excellent physical and chemical properties, high oral bioavailability, excellent drugability, and are well-suited for pharmaceutical preparation, application, and preservation.
    Type: Grant
    Filed: December 18, 2020
    Date of Patent: July 12, 2022
    Assignees: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES, SUZHOU VIGONVITA LIFE SCIENCES CO., LTD., TOPHARMAN SHANGHAI CO., LTD.
    Inventors: Jingshan Shen, Yang He, Zhen Wang, Jianfeng Li, Yongjian Liu, Jin Suo, Guanghui Tian, Weiming Chen, Feipu Yang, Yu Wang, Xiangrui Jiang, Rongxia Zhang, Hualiang Jiang
  • Patent number: 11384055
    Abstract: Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with the enzyme glycolate oxidase (GO). Such diseases or disorders include, for example, disorders of glyoxylate metabolism, including primary hyperoxaluria, that are associated with production of excessive amounts of oxalate.
    Type: Grant
    Filed: December 28, 2018
    Date of Patent: July 12, 2022
    Assignee: BIOMARIN PHARMACEUTICAL INC.
    Inventors: Bing Wang, Qi Chao
  • Patent number: 11384099
    Abstract: Pyrazolopyridinone compounds, the pharmaceutical compositions comprising said compounds, and the use of said compounds as FGFR (fibroblast growth factor receptor) inhibitors and their use in the treatment of diseases, e.g. cancer.
    Type: Grant
    Filed: November 23, 2018
    Date of Patent: July 12, 2022
    Assignee: Janssen Pharmaceutica NV
    Inventors: Haibing Guo, Zhao-Kui Wan, Luoheng Qin, Qian Liu, Wing Shun Cheung
  • Patent number: 11377443
    Abstract: A compound which is an arylimidazolyl isoxazole of formula (I): (Formula (I)) or a pharmaceutically acceptable salt thereof. The compound has activity in modulating the activity of p300 and/or CBP and is used to treat cancer, particularly prostate cancer.
    Type: Grant
    Filed: May 14, 2020
    Date of Patent: July 5, 2022
    Assignee: CELLCENTRIC LIMITED
    Inventors: Neil Anthony Pegg, Stuart Thomas Onions, David Michel Adrien Taddei, Jonathan Shannon, Silvia Paoletta, Richard James Brown, Don Smyth, Gareth Harbottle
  • Patent number: 11376246
    Abstract: Methods of treating patients diagnosed with cancer harboring an IDH-1 mutation are provided, including the therapeutic administration of a certain inhibitor of a mutant IDH-1 as a single agent, or in combination with azacitidine (AZA).
    Type: Grant
    Filed: November 25, 2019
    Date of Patent: July 5, 2022
    Assignee: FORMA Therapeutics, Inc.
    Inventors: Patrick F. Kelly, Alan Collis, Jeff Davis, Duncan Walker, Susan Ashwell, Blythe Thomson, Wei Lu
  • Patent number: 11370788
    Abstract: Imidazo[4,5-c]quinoline compounds having a substituent that is attached at the N?1 position by a branched group, single enantiomers of the compounds, pharmaceutical compositions containing the compounds, and methods of making the compounds are disclosed. Methods of use of the compounds as immune response modifiers, for inducing cytokine biosynthesis in humans and animals, and in the treatment of diseases including infectious and neoplastic diseases are also disclosed.
    Type: Grant
    Filed: February 25, 2019
    Date of Patent: June 28, 2022
    Assignee: 3M Innovative Properties Company
    Inventors: George W. Griesgraber, Kevin J. Bechtold
  • Patent number: 11365202
    Abstract: The present invention provides a new artemisinin-dipeptidyl vinyl based compound of Formula (I) or a pharmaceutically acceptable salt thereof and a process for the preparation thereof. The present invention further also provides a pharmaceutical composition comprising compounds of Formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent or excipient to treat malaria.
    Type: Grant
    Filed: April 16, 2019
    Date of Patent: June 21, 2022
    Assignees: Council of Scientific and Industrial Research, International Centre for Genetic Engineering and Biotechnology (ICGEB)
    Inventors: Asish Kumar Bhattacharya, Eswar Kumar Aratikatla, Pawan Malhotra, Asif Mohmmed
  • Patent number: 11365186
    Abstract: This application relates to substituted benzimidazoles, compositions comprising them and their uses in the treatment of diseases and conditions in which inhibition of a bromodomain is indicated. For example, the application relates to substituted benzimidazoles and to their use as bromodomain inhibitors. The present application is also related to the treatment or prevention of proliferative disorders, auto-immune disorders, inflammatory disorders, dermal disorders, and neoplasms, including tumors and/or cancers.
    Type: Grant
    Filed: May 22, 2020
    Date of Patent: June 21, 2022
    Assignee: EPIGENETIX, INC.
    Inventors: Mehrnaz Pourashraf, Guillaume Jacquemot, Stephen Claridge, Malken Bayrakdarian, Shawn Johnstone, Jeffrey S. Albert, Andrew Griffin
  • Patent number: 11352357
    Abstract: The present invention relates to a medicament for treating or preventing a disease related to orexin receptor, especially orexin type 2 receptor, comprising a new compound having a urea structure or a pharmaceutically acceptable salt thereof as an active ingredient. In more detail, the present invention relates to a medicament for treating or preventing narcolepsy, idiopathic hypersomnia, hypersomnia, sleep apnea syndrome, etc.
    Type: Grant
    Filed: November 15, 2021
    Date of Patent: June 7, 2022
    Assignee: Sumitomo Dainippon Pharma Co., Ltd.
    Inventors: Eiji Ideue, Masafumi Komiya, Shoukou Lee, Shunichiro Uesugi, Yuta Funakoshi
  • Patent number: 11352331
    Abstract: Disclosed are a crystal of a 4-(naphthalene-1-yl)-4H-1,2,4-triazole compound (1) and a preparation method therefor, also comprised are applications of the crystal in preparing a medicament for treating an abnormal uric acid level-related disease.
    Type: Grant
    Filed: December 17, 2018
    Date of Patent: June 7, 2022
    Assignee: MEDSHINE DISCOVERY
    Inventors: Jianfei Wang, Yang Zhang, Jian Li, Shuhui Chen
  • Patent number: 11352353
    Abstract: A heterocyclic compound which is an inhibitor of FGFR4 (fibroblast growth factor receptor 4) is described. Specifically, a compound represented by the following formula (I), including an isomer (enantiomer or diastereomer) which may be present, or a pharmaceutically acceptable salt thereof, prodrugs, deuterated derivatives, hydrates, solvates, are described. The definition of each group in the formula (I) is as described in the specification. The compounds have FGFR4 inhibitory activity and can be used for the prevention or treatment of diseases associated with FGFR4 activity or expression, and can also be used in combination with other drugs for the treatment of various related diseases, as described.
    Type: Grant
    Filed: May 27, 2017
    Date of Patent: June 7, 2022
    Assignee: Hangzhou Innogate Pharma Co., Ltd.
    Inventors: Hancheng Zhang, Shifeng Liu, Xiangyang Ye
  • Patent number: 11352343
    Abstract: The present invention provides novel compounds of any one of Formulae (I)-(III), and pharmaceutical compositions thereof. Also provided are particles (e.g., nanoparticles) comprising compounds of Formula (I)-(III) and pharmaceutical compositions thereof that are mucus penetrating. The invention also provides methods and kits for using the inventive compounds, and pharmaceutical compositions thereof, for treating and/or preventing diseases associated with abnormal or pathological angiogenesis and/or aberrant signaling of a growth factor (e.g., vascular endothelial growth factor (VEGF)), such as proliferative diseases (e.g., cancers, benign neoplasms, inflammatory diseases, autoimmune diseases) and ocular diseases (e.g., macular degeneration, glaucoma, diabetic retinopathy, retinoblastoma, edema, uveitis, dry eye, blepharitis, and post-surgical inflammation) in a subject in need thereof.
    Type: Grant
    Filed: June 12, 2020
    Date of Patent: June 7, 2022
    Assignee: Kala Pharmaceuticals, Inc.
    Inventors: Winston Zapanta Ong, Pawel Wojciech Nowak, John Thomas Feutrill, Jinsoo Kim
  • Patent number: 11345678
    Abstract: The invention relates to a benzopyrazole compound used as RHO kinase inhibitor, a pharmaceutical composition and uses thereof for preparing an RHO kinase inhibiting drug, and more specifically to said compound of formula (I-1), a pharmaceutically acceptable salt and isomer thereof.
    Type: Grant
    Filed: April 18, 2019
    Date of Patent: May 31, 2022
    Assignee: MEDSHINE DISCOVERY INC.
    Inventors: Lingyun Wu, Jun Yin, Cailin Wang, Zheming Xiao, Jian Li, Shuhui Chen
  • Patent number: 11345702
    Abstract: Disclosed herein are compounds that can inhibit 15-hydroxyprostaglandin dehydrogenase. Such compounds may be administered to subjects that may benefit from modulation of prostaglandin levels.
    Type: Grant
    Filed: September 24, 2021
    Date of Patent: May 31, 2022
    Assignee: MYOFORTE THERAPEUTICS, INC.
    Inventors: Roopa Rai, Robert Booth, Michael J. Green
  • Patent number: 11345701
    Abstract: The invention relates to a KRAS mutant protein inhibitors of formula (I), a composition containing the inhibitors and the use thereof.
    Type: Grant
    Filed: August 20, 2021
    Date of Patent: May 31, 2022
    Assignee: JACOBIO PHARMACEUTICALS CO., LTD.
    Inventors: Amin Li, Sujing Li, Peng Wang, Chaojie Dang, Dan Liu
  • Patent number: 11339162
    Abstract: Compounds of Formula (I) are estrogen receptor alpha modulators, where the variables in Formula (I) are described in the disclosure. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions that are estrogen receptor alpha dependent and/or estrogen receptor alpha mediated, including conditions characterized by excessive cellular proliferation, such as cancer.
    Type: Grant
    Filed: December 20, 2021
    Date of Patent: May 24, 2022
    Assignee: Recurium IP Holdings, LLC
    Inventors: Guobao Zhang, Peter Qinhua Huang, Kevin Duane Bunker, Sayee Gajanan Hegde
  • Patent number: 11339161
    Abstract: The present invention relates to triazolo pyridines of formula (II) and their use as modulators of #-secretase. In particular, the present invention relates to compounds which interfere with #-secretase and/or its substrate and therefore modulate the formation of A? peptides. Accordingly these compounds can be used for the treatment of A?-related pathologies, e.g. Alzheimer's disease.
    Type: Grant
    Filed: December 18, 2018
    Date of Patent: May 24, 2022
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Niklas Heine, Christian Eickmeier, Kai Gerlach, Ulrike Gross